Since 1915, when Oppenheim recommended trichloroethylene as a therapeutic agent, numerous investigators have published contradictory opinions regarding the efficacy of the drug to relieve the pain of trigeminal neuralgia. Reports of beneficial results following the use of the drug range from 85 per cent complete relief, as reported by Plessner,1 to only 5 per cent complete relief, as reported by Seelert2 in a later paper. More recently the drug has been used with some success as a hypalgesic in the treatment of angina pectoris.3 The further clinical applicability of the drug has been investigated by Striker and his associates,4 who have successfully employed it to induce general anesthesia during surgical operations. The clinical observations of these investigators, together with the published results of laboratory studies of the effect of the purified drug on laboratory animals, have led to the general feeling that the relatively pure drug
EICHERT H. TRICHLOROETHYLENE INTOXICATION. JAMA. 1936;106(19):1652–1654. doi:10.1001/jama.1936.02770190028010
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: